Eat a ‘flavodiet' to stay physically and mentally strong when older, new study suggests
Among the countless bioactive compounds in plants, flavonoids have received considerable attention in recent years for their influence on health.
Research suggests, for example, that a high intake of these protective phytochemicals can guard against cardiovascular disease, Type 2 diabetes, certain cancers, cognitive decline and dementia.
Now, new study findings add to mounting evidence for flavonoids' healthy-aging benefits.
The findings suggest that a high flavonoid diet – and a regular intake of specific flavonoid-rich foods – can lower the risks of developing frailty, impaired physical function and poor mental health in our 70s and beyond.
What are flavonoids?
Flavonoids are a large family of more than 5,000 phytochemicals in fruits, vegetables and other plant foods. Dietary flavonoids are categorized into six subclasses, each one residing in certain foods and having specific health properties.
The subclasses are anthocyanins (berries, red grapes, plums, red cabbage), flavan-3-ols (green and black tea, cocoa), flavonols (onions, kale, arugula, watercress), flavanones (citrus fruit), flavones (parsley, thyme, celery) and isoflavones (soybeans, lentils, chickpeas).
About the latest research
The study, published last month in the American Journal of Clinical Nutrition, investigated the relationship between intake of flavonoids and flavonoid-rich foods and frailty, impaired physical function and poor mental health, indicators of unhealthy aging.
The research team analyzed data from two U.S. studies: the Nurses' Health Study (females) and the Health Professionals Follow-up Study (males). A total of 62,743 women and 23,687 men, ages 60 and older, were followed for 24 and 12 years, respectively.
Information on age, body measurements, lifestyle behaviours, medication use, family medical history and recent personal health diagnoses was collected every two years.
Participants provided detailed dietary information at baseline and every four years thereafter. A 'flavodiet' score was calculated for each participant by adding up intakes (servings/day) of key food contributors to total flavonoid intake.
Key flavonoid-rich foods included blueberries, strawberries, grapes, raisins, apples, oranges, orange juice, grapefruit, grapefruit juice, tea, red wine, onion and sweet bell peppers.
Frailty, measured every four years, was defined as having at least three of five criteria: fatigue, poor strength, reduced aerobic capacity, at least five chronic illnesses and a weight loss of five per cent or more.
Participants reported perceived physical limitations in basic mobility, daily living tasks and performing various moderate and vigorous activities. They were also asked about symptoms of depression, anxiety and overall well-being.
High flavodiet scores protective
Among participants in the Nurses' Health Study, those with the highest flavodiet scores had a 15 per cent lower risk of developing frailty, a 12 per cent lower risk of developing impaired physical function and a 12 per cent lower risk of developing poor mental health during the study period compared to women with the lowest flavodiet scores.
The highest intakes of tea, red wine, apples, blueberries, strawberries, oranges and orange juice – and increased intakes of these foods over the study period – were associated with a lower risk of all three outcomes in women.
Surprisingly, fewer protective effects were seen in men.
Participants in Health Professionals Follow-up Study with the highest (versus lowest) flavodiet scores were 18 per cent less likely to have poor mental health scores.
Higher intakes of tea and blueberries were tied to a lower risk of poor mental health. Intakes of key flavonoid-rich foods were not associated with risk of frailty or impaired physical function.
It's unclear if there are differences in diet-related risks factors for health in aging between males and females. The findings in men may also have been influenced by the shorter follow-up of 12 years, resulting in fewer outcomes being reported.
The researchers also found that a daily increase of three servings of flavonoid-rich foods and beverages during the study translated to a 6 to 11 per cent lower risk across all three outcomes in females and a 15 per cent lower risk of poor mental health in males.
To arrive at their findings, the researchers accounted for other influential factors including age, smoking status, family health history, personal health, physical activity, body mass index and calorie intake.
How flavonoids safeguard healthy aging
The new findings are in keeping with previous studies linking high intakes of flavonoids or flavonoid-rich foods to a lower risk of frailty, impaired physical function and depression.
Flavonoids' strong antioxidant and anti-inflammatory effects are thought to protect cells from damage caused by oxidative stress and inflammation, factors that accumulate during aging.
Elevated levels of inflammation can lead to loss of muscle mass and strength.
Inflammatory immune compounds can also communicate with the brain, affecting mood and energy levels.
Takeaway
The findings suggest a modest, yet doable, dietary adjustment – increasing your daily intake of flavonoid-rich foods by three servings – can optimize healthy aging and quality of life.
One serving is equivalent to one half-cup of blueberries, strawberries or grapes, one ounce of raisins, one whole orange or apple, one half of a grapefruit, five ounces of citrus fruit juice, eight ounces of tea, one slice of raw onion or one half-cup cooked or one-quarter of a small bell pepper.
Leslie Beck, a Toronto-based private practice dietitian, is director of food and nutrition at Medcan. Follow her on X @LeslieBeckRD
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
4 hours ago
- CTV News
Smoke from wildfires triggers special air quality statement in Ontario
A haze from the western wildfires as seen from Waterloo Region on June 5, 2025. The long weekend may be a smoky one for people in most of Ontario. Environment Canada issued a special air quality statement at 1:28 p.m. Saturday, warning of poor air quality and reduced visibility. 'Smoke from forest fires is expected to continue to spread south into southern Ontario this afternoon and evening. The wildfire smoke may persist for much of the weekend for parts of southern Ontario,' the notice read. The smoke is billowing from wildfires burning in the Prairies. Environment Canada warns air quality and visibility could fluctuate over short distances and vary 'considerably' from hour to hour. People living in the effected areas, including Waterloo Region, Wellington County, Brant County, Perth County and Oxford County, were encouraged to limit time outdoors and consider reducing or rescheduling outdoor activities. The weather office said some people are more likely to be impacted by the smoke, including people aged 65 or older, pregnant people, infants and young children, and people with pre-existing conditions. Anyone working outdoors for long periods of time could also feel the effects. Some people may experience eye, nose and throat irritation, headaches or a mild cough. Rare, but less common, symptoms include wheezing, chest pain and severe coughs.


CBC
7 hours ago
- CBC
Expert discusses potential impact of Trump's demand to slash drug prices in U.S.
U.S. President Donald Trump has issued a direct warning to top pharmaceutical companies, demanding they slash drug prices. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses concerns and how this could impact drug prices in Canada.


Globe and Mail
9 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.